Acylsulfonamidderivate und Ihre Verwendung zur Behandlung von Krebs
EP4810485
23. September 2026
Anmelder: Qubit Pharmaceuticals 🇫🇷
Details
- Veröffentlichungs-Nr.
- EP4810485
- Anmeldetag
- 17. März 2025
- Veröffentlichung
- 23. September 2026
- Rechtsraum
- EP
Abstract
The present disclosure describes acylsulfonamide compounds of Formula (I), and pharmaceutically acceptable salts thereof, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as inhibitors of KAT6A with improved selectivity particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.
Anmelder
- Firma
- Qubit Pharmaceuticals
- Land
- 🇫🇷 Frankreich
Vertreten von
-
A.P.I. Conseil
A.P.I. Conseil · Pau